Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pipelines are rapidly expanding beyond lutetium into next-generation alpha emitters and novel targets, and developers are racing to bring transformative radioligand therapies to patients. As the field matures, the industry's greatest challenges involve clinical translation, isotope availability, manufacturing scale-up and regulatory alignment. The 8th Targeted Radiopharmaceuticals Summit Europe unites the scientific, clinical, manufacturing, regulatory and commercial leaders driving this transformation to build the blueprint for Europe's next generation of targeted radiopharmaceuticals. Join your peers to: Discover the latest breakthroughs across novel targets, alpha emitters, Auger therapies and next-generation radiopharmaceutical platforms to strengthen your discovery and preclinical strategy. Learn how leading developers are optimising trial design, dosimetry, combination strategies and earlier-line treatment approaches to generate stronger clinical evidence and maximise patient impact. Overcome isotope availability, GMP manufacturing, automation, logistics and supply chain bottlenecks to support scalable clinical development and future commercial success. Hear directly from MHRA, Swissmedic, the IAEA and the Office for Nuclear Regulation to understand the latest regulatory expectations and accelerate European clinical and commercial development. This is your opportunity to join Europe's most comprehensive, end-to-end forum dedicated to targeted radiopharmaceutical development, where discovery, clinical translation, manufacturing, regulation and commercial strategy come together to accelerate the next generation of radioligand therapies from discovery to patients.

Description supplied by the event organiser.